Experiment: 2LGJ

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	1mM [U-98% 15N] MsPTH-1, 20mM sodium phosphate-2, 50mM sodium chloride-3, 1mM DTT-4, 1mM AEBSF protease inhibitor-5, 1% sodium azide-6	93% H2O/7% D2O	50	6.5	ambient	303
2	3D HNCACB	1mM [U-98% 13C; U-98% 15N] MsPTH-7, 20mM sodium phosphate-8, 50mM sodium chloride-9, 1mM DTT-10, 1mM AEBSF protease inhibitor-11, 1% sodium azide-12	93% H2O/7% D2O	50	6.5	ambient	303
3	3D CBCA(CO)NH	1mM [U-98% 13C; U-98% 15N] MsPTH-7, 20mM sodium phosphate-8, 50mM sodium chloride-9, 1mM DTT-10, 1mM AEBSF protease inhibitor-11, 1% sodium azide-12	93% H2O/7% D2O	50	6.5	ambient	303
4	3D HNCA	1mM [U-98% 13C; U-98% 15N] MsPTH-7, 20mM sodium phosphate-8, 50mM sodium chloride-9, 1mM DTT-10, 1mM AEBSF protease inhibitor-11, 1% sodium azide-12	93% H2O/7% D2O	50	6.5	ambient	303
5	3D HNCO	1mM [U-98% 13C; U-98% 15N] MsPTH-7, 20mM sodium phosphate-8, 50mM sodium chloride-9, 1mM DTT-10, 1mM AEBSF protease inhibitor-11, 1% sodium azide-12	93% H2O/7% D2O	50	6.5	ambient	303
6	3D HN(CA)CO	1mM [U-98% 13C; U-98% 15N] MsPTH-7, 20mM sodium phosphate-8, 50mM sodium chloride-9, 1mM DTT-10, 1mM AEBSF protease inhibitor-11, 1% sodium azide-12	93% H2O/7% D2O	50	6.5	ambient	303
7	3D H(CCO)NH	1mM [U-98% 13C; U-98% 15N] MsPTH-7, 20mM sodium phosphate-8, 50mM sodium chloride-9, 1mM DTT-10, 1mM AEBSF protease inhibitor-11, 1% sodium azide-12	93% H2O/7% D2O	50	6.5	ambient	303
8	3D C(CO)NH	1mM [U-98% 13C; U-98% 15N] MsPTH-7, 20mM sodium phosphate-8, 50mM sodium chloride-9, 1mM DTT-10, 1mM AEBSF protease inhibitor-11, 1% sodium azide-12	93% H2O/7% D2O	50	6.5	ambient	303
9	3D HCCH-TOCSY	1mM [U-98% 13C; U-98% 15N] MsPTH-7, 20mM sodium phosphate-8, 50mM sodium chloride-9, 1mM DTT-10, 1mM AEBSF protease inhibitor-11, 1% sodium azide-12	93% H2O/7% D2O	50	6.5	ambient	303
10	3D 1H-15N NOESY	1mM [U-98% 15N] MsPTH-1, 20mM sodium phosphate-2, 50mM sodium chloride-3, 1mM DTT-4, 1mM AEBSF protease inhibitor-5, 1% sodium azide-6	93% H2O/7% D2O	50	6.5	ambient	303
11	2D 1H-13C HSQC aliphatic	0.9mM [U-98% 13C; U-98% 15N] MsPTH-13, 20mM sodium phosphate-14, 50mM sodium chloride-15, 1mM DTT-16, 1mM AEBSF protease inhibitor-17, 1% sodium azide-18	100% D2O	50	6.5	ambient	303
12	2D 1H-13C HSQC aromatic	0.9mM [U-98% 13C; U-98% 15N] MsPTH-13, 20mM sodium phosphate-14, 50mM sodium chloride-15, 1mM DTT-16, 1mM AEBSF protease inhibitor-17, 1% sodium azide-18	100% D2O	50	6.5	ambient	303
13	3D 1H-13C NOESY aliphatic	0.9mM [U-98% 13C; U-98% 15N] MsPTH-13, 20mM sodium phosphate-14, 50mM sodium chloride-15, 1mM DTT-16, 1mM AEBSF protease inhibitor-17, 1% sodium azide-18	100% D2O	50	6.5	ambient	303
14	2D 1H-13C NOESY aromatic	0.9mM [U-98% 13C; U-98% 15N] MsPTH-13, 20mM sodium phosphate-14, 50mM sodium chloride-15, 1mM DTT-16, 1mM AEBSF protease inhibitor-17, 1% sodium azide-18	100% D2O	50	6.5	ambient	303
15	HB(CBCGCE)HE	1mM [U-98% 13C; U-98% 15N] MsPTH-7, 20mM sodium phosphate-8, 50mM sodium chloride-9, 1mM DTT-10, 1mM AEBSF protease inhibitor-11, 1% sodium azide-12	93% H2O/7% D2O	50	6.5	ambient	303
16	HB(CBCGCD)HD	1mM [U-98% 13C; U-98% 15N] MsPTH-7, 20mM sodium phosphate-8, 50mM sodium chloride-9, 1mM DTT-10, 1mM AEBSF protease inhibitor-11, 1% sodium azide-12	93% H2O/7% D2O	50	6.5	ambient	303

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Varian	INOVA	600
2	Bruker	AVANCE	800

NMR Refinement
Method	Details	Software
molecular dynamics		NMRPipe

NMR Ensemble Information
Conformer Selection Criteria	target function
Conformers Calculated Total Number	200
Conformers Submitted Total Number	10
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
2	processing	NMRDraw		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
3	chemical shift assignment	CARA	1.8.4	Keller and Wuthrich
4	structure solution	TALOS	+	Cornilescu, Delaglio and Bax
5	structure solution	CYANA	3.0	Guntert, Mumenthaler and Wuthrich
6	refinement	CNS	1.2	Brunger, Adams, Clore, Gros, Nilges and Read

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.